Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
52 Cards in this Set
- Front
- Back
Onset of ADHD is @ ___ years, must occur by age ___
|
Onset of ADHD is @ *3* years old, must occur by age *7*
|
|
Diagnosis of ADHD: ___ number of symptoms must be present for ___ months
|
Diagnosis of ADHD: *6* or more of the symptoms must be presnt for *6* months
|
|
Prevailing explanation of ADHD: what brain regions is responsible for inability to control thier behavior, resist distractions, & develop an awareness of space & time?
|
Prevailing explanation of ADHD: *the prefrontal cortex* is responsible for inability to control thier behavior, resist distractions, & develop an awareness of space & time?
|
|
Effective treatment for ADHD involved the modulation of which 2 neurotransmitters?
|
Effective treatments for ADHD involve *DA & NE* modulations to improve executive function & regulate arousal
|
|
ADHD treatment:
1st line treatment: ? 2nd line treatment: ? 3rd line treatment: ? 4th line treatment: ? |
ADHD treatment:
1st line treatment: stimulants (methylphenidate & amphetamines) 2nd line treatment: atomoxetine or buproprion 3rd line treatment: TCA 4th line treatment: alpha2-agonist |
|
What type of behavioral intervention for ADHD is the following scenerio?
Child completes an assignment & is permitted to play on the computer. |
Child completes an assignment & is permitted to play on the computer.
Positive reinforcement |
|
What type of behavioral intervention for ADHD is the following scenerio?
Child hits sibling impulsively & is required to sit for 5 minutes in the corner of the room. |
Child hits sibling impulsively & is required to sit for 5 minutes in the corner of the room.
Time-out |
|
What type of behavioral intervention for ADHD is the following scenerio?
Child loses free-time privileges for not completed hmwk. |
Child loses free-time privileges for not completed hmwk.
Response cost |
|
What type of behavioral intervention for ADHD is the following scenerio?
Child earns starts for completing assignments & loses stars for getting out of seat. The child cashes the sum of starts at the end of the week for a prize. |
Child earns starts for completing assignments & loses stars for getting out of seat. The child cashes the sum of starts at the end of the week for a prize.
Token economy |
|
MAO of methylphenidate & amphetamines:
block reuptake of which 2 neurotransmitters? amphetamine also increases ___> |
Methylphenidate & amphetamines block *DA & NE* reuptake.
Amphetamines also increase *catecholamine release* |
|
Adverse effects of stimulants:
height deficit of ___ inches/year during 1-3 years of treatment |
Adverse effects of stimulants:
height deficit of *0.4* inches/year during 1-3 years of treatment |
|
Adverse effects of stimulants:
Average weight decrease of ___ lbs during 1st year & ___ lbs in 2nd year. |
Adverse effects of stimulants:
Average weight decrease of *6.6* lbs during 1st year & *2.6* lbs in 2nd year. |
|
Atomoxtine is a ______ (MOA) & the first nonstimulant FDA approved for ADHD.
|
Atomoxtine is a *selective NE reuptake inhibitor* (MOA) & the first nonstimulant FDA approved for ADHD.
|
|
Metabolism of atomoxetine?
|
Atomoxetine
metabolized by CYP 2D6 |
|
Tourette's Disorder:
Most notable brain regions? |
Tourette's Disorder:
Most notable brain regions? basal ganglia & caudate nucleus |
|
Tourette's Disorder:
What is the most widely prescribed agent? |
Tourette's Disorder:
What is the most widely prescribed agent? Clonidine |
|
Tourette's Disorder:
___ (atypical antipsychotic) was reported NOT to be effective |
Tourette's Disorder:
*Clozapine* (atypical antipsychotic) was reported NOT to be effective |
|
____ (drug class) should be used before haloperidol & pimozide (for safety reasons)
|
*Atypical antipsychotics* (drug class) should be used before haloperidol & pimozide (for safety reasons)
|
|
Metabolism of haloperidol & pimozide?
|
Metabolism of haloperidol & pimozide?
CYP 3A4 |
|
Oral tablet used for nocturnal enureses?
|
Desmopressin
|
|
Hyponatremia is an adverse effect of _____ & defined as _____.
|
Hyponatremia is an adverse effect of *desmopressin* & defined as *<135 mEq/L*.
|
|
What is: abnormality in the amount, quality, or timing of sleep?
|
Dyssomnias: abnormality in the amount, quality, or timing of sleep?
|
|
Sleep cycle: consists of two major phases - REM (___%) & NREM (___%)
One cycle is about ____ min |
Sleep cycle: consists of two major phases - REM (25%) & NREM (75%)
One cycle is about 70-120 min |
|
___ (neurotransmitter): maintains normal sleep pattern
|
NE: maintains normal sleep patterns
|
|
___ (neurotransmitter): sleep regulation
|
serotonin: sleep regulation
|
|
___ (neurotransmitter): has an alterting effect
|
DA: has an alterting effect
|
|
Diphenhydramine metabolism?
|
Diphenhydramine is a potent CYP 2D6 inhibitor (Inc conc of other drugs)
|
|
Zolpidem metabolism?
|
Zolpidem is metabolized by CYP 3A4
(interaction with ketoconazole & rifampin) |
|
Zaleplon metabolism?
|
Zaleplon metabolized by aldehyde oxidase
|
|
Zaleplon drug interactions?
|
Zaleplon drug interactions:
Cimetidine INC Cpss Rifampin DEC Cpss |
|
Eszopiclone metabolism?
|
Eszopiclone metabolized by CYP 3A4 & 2E1 (interaction with alcohol)
|
|
Ramelteon metabolism?
|
Ramelteon metabolized by CYP 1A2 (major) & 2C & 3A4 (minor)
*Do not take with food! |
|
Ramelteon drug interactions?
|
fluvoxamine INC AUC
fluconazole INC AUC (2C inhibitor) ketoconazole INC AUC rifampin DEC AUC (enzyme inducer) |
|
Benzo's effect on sleep stages?
|
Benzo's increase stage 2 sleep, decreases durations of stages 1, 2, & 4.
BZ's do not decrease REM. |
|
Benzo's with clinically significant metabolites
|
Benzo's with clinically significant metabolites:
Flurazepam (Dalmane) Quazepam (Doral) |
|
Treatment for narcolepsy?
|
Treatment for narcolepsy:
- stimulants - antidepressants - GHB |
|
Modafinil metabolism?
|
Modafinil metabolism:
CYP 2C19 inhibitor (inc other drug conc) CYP 3A4 inducer (dec other drug conc) |
|
Drug FDA approved in 2002 for cataplexy
|
GHB (as sodium oxybate - Xyrem)
FDA approved n 2002 for cataplexy |
|
Treatment of sleepwalking & sleep terrors
|
Treatment of sleepwalking & sleep terrors:
BZ's, SSRI's, & TCA's |
|
Treatment of sleep-related eating disorder
|
Treatment of sleep-related eating disorder:
Tx with opiates, l-dopa, or topiramate |
|
Core features of anorexia nervosa (AN)
|
Core features of anorexia nervosa (AN)
refusal to maintain minimal body weight (>85% normal body weight or BMI >17.5kg/m2) Amenorrhea for the last 3 cycles |
|
BMI calculation?
|
BMI = [(weight (lbs) x 703) / (height squared [in])] x 703
|
|
Which 3 neurotransmitters contribute to eating behavior?
|
5-HT, NE, & DA contribute to eating behavior
|
|
Preferred agents for anorexia nervosa (AN)?
|
SSRI's are preferred agents due to safety (TCA's & MAOI's have anticholinergic & cardiovascular issues)
|
|
True/False: Antipsychotics & appetite suppressants have a role in BN.
|
FALSE: Antipsychotics & appetite suppressants have NO role in BN.
|
|
AED serum concentration ranges:
Phenobarbital |
AED serum concentration ranges:
Phenobarbital = 10-40 mcg/mL |
|
AED serum concentration ranges:
Phenytoin |
AED serum concentration ranges:
Phenytoin = 10-20 mcg/mL |
|
AED serum concentration ranges:
Ethosuximide |
AED serum concentration ranges:
Ethosuximide = 40-80 mcg/mL |
|
AED serum concentration ranges:
Valproic acid |
AED serum concentration ranges:
Valproic acid = 50-150 mcg/mL |
|
AED serum concentration ranges:
Carbamazepine |
AED serum concentration ranges:
Carbamazepine = 4-14 mcg/mL |
|
Fetal malformations:
Carbamazepine & Valproic acid can cause ___ ___ & ___ can cause congenital heart malformations |
Fetal malformations:
Carbamazepine & Valproic acid can cause *spina bifida* *barbituates & phenytoin* can cause congenital heart malformations |
|
Drugs with non-linear PK:
|
Drugs with non-linear PK:
phenytoin VPA (dose > 2.5 gm/day) ethosuximide gabapentin pregabalin carbamazepine |